Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Dabrafenib + Trametinib

Aliases
dabrafenib, dabrafenib and trametinib, Dabrafenib and Trametinib, dabrafenib + trametinib
Name
Tafinlar
FDA Approved
Yes

8 clinical trials

1 organization

2 drugs

2 abstracts

10 indications

1 document

Indication
Melanoma
Indication
NSCLC
Indication
BRAF V600 Mutation
Indication
MET Exon 14 Mutation
Indication
Craniopharyngioma
Indication
Cancer
Indication
Tumor
Indication
Neoplasia
Drug
Dabrafenib
Drug
trametinib
Indication
Small Intestine Adenocarcinoma
Indication
Thyroid Cancer
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CDRB436B2005CM to Provide Access to Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
Status:
Clinical trial
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Status: Completed, Estimated PCD: 2022-01-27
Clinical trial
Impact of Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib) on Patients Quality of Life (QoL) and Clinical Outcomes in Portuguese Real World Setting
Status: Completed, Estimated PCD: 2022-06-07
Clinical trial
A Phase II, Two Parallel Group Study of Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma
Status: Recruiting, Estimated PCD: 2027-09-10
Clinical trial
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10426
Abstract
CT083 / 11 - Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
Clinical trial
Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study
Status: Recruiting, Estimated PCD: 2024-12-01
Document
DailyMed Label: Tafinlar
Organization
Novartis Pharmaceuticals Corporation